Medical Devices

31 tickers rated Hold in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Novanta Inc.
NOVT·Technology
B ★★★Hold
Current$123.31
Target$129.00
Return+4.6%
Nov 12, 2026

Novanta benefits from specialized automation technology and expanding recurring medical revenue, but Riverpoint acquisition debt, future dilution, and demanding cash-flow growth expectations constrain near-term investment returns.

Score
65
iRhythm Holdings, Inc.
IRTC·Healthcare
B ★★★Hold
Current$90.22
Target$123.44
Return+36.8%
Nov 8, 2026

iRhythm's differentiated cardiac monitoring platform offers long-term growth through expanding clinical adoption and improved operating leverage, but telemetry integration setbacks, regulatory exposure, and weak cash conversion threaten its recovery.

Score
66
TransMedics Group, Inc.
TMDX·Healthcare
B ★★★Hold
Current$88.24
Target$103.91
Return+17.8%
Nov 8, 2026

TransMedics combines differentiated organ-preservation technology with a scalable transplant logistics platform, offering substantial long-term growth potential, but weak cash conversion and operating-margin pressure constrain near-term upside.

Score
67
Teleflex Incorporated
TFX·Healthcare
B ★★★Hold
Current$150.87
Target$164.10
Return+8.8%
Nov 8, 2026

Teleflex could unlock higher per-share earnings through portfolio simplification, debt reduction, and medical device innovation, but weak capital returns and uncertain recurring margins constrain the investment case.

Score
72
Warby Parker Inc.
WRBY·Healthcare
B ★★★Hold
Current$25.48
Target$28.36
Return+11.3%
Nov 8, 2026

Warby Parker combines a growing optical retail network with a promising Intelligent Eyewear opportunity, but demanding valuation multiples and uncertain new-product economics limit its current margin of safety.

Score
67
Haemonetics Corporation
HAE·Healthcare
B ★★★Hold
Current$119.93
Target$127.16
Return+6.0%
Nov 8, 2026

Haemonetics offers recurring plasma disposables, improving cash generation, and new vascular closure growth opportunities, but its elevated historical valuation and CSL rollout dependence limit near-term upside.

Score
71
ICU Medical, Inc.
ICUI·Healthcare
B ★★★Hold
Current$172.11
Target$183.35
Return+6.5%
Nov 8, 2026

ICU Medical offers a credible infusion-therapy turnaround supported by recurring consumables and stronger cash flow, but modest ROIC, acquisition-related debt, and product-quality risks limit its margin of safety.

Score
72
Cardinal Health, Inc.
CAH·Healthcare
B ★★★Hold
Current$271.72
Target$258.00
Return-5.0%
Nov 8, 2026

Cardinal Health's entrenched pharmaceutical distribution network and expanding specialty services support durable earnings growth, but its historically elevated valuation and customer concentration limit near-term upside.

Score
70
Becton, Dickinson and Company
BDX·Healthcare
B ★★★Hold
Current$211.88
Target$217.80
Return+2.8%
Nov 8, 2026

Becton Dickinson combines recurring medical-device demand, strong cash generation, and post-separation efficiency potential, but modest organic growth, leverage, and the recent stock-price recovery constrain near-term upside.

Score
74
Solventum Corporation
SOLV·Healthcare
B ★★★Hold
Current$90.38
Target$100.04
Return+10.7%
Nov 8, 2026

Solventum offers a credible medical technology turnaround supported by durable clinical franchises and portfolio simplification, but weak cash conversion, substantial leverage, and separation execution risks constrain near-term upside.

Score
65
Bio-Rad Laboratories, Inc.
BIO·Healthcare
B ★★★Hold
Current$381.57
Target$397.83
Return+4.3%
Nov 7, 2026

Bio-Rad combines resilient clinical diagnostics, improving adjusted margins, and a valuable Sartorius stake, but weak Life Science demand and low operating returns limit near-term upside.

Score
71
Edwards Lifesciences Corporation
EW·Healthcare
B ★★★Hold
Current$102.14
Target$103.50
Return+1.3%
Nov 7, 2026

Edwards Lifesciences combines a durable TAVR franchise with fast-growing mitral and tricuspid therapies, but demanding cash-flow valuation and competition limit near-term upside despite strong clinical momentum.

Score
73